XML 34 R27.htm IDEA: XBRL DOCUMENT v3.26.1
Segment (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Summary of Reconciles Reported Revenues to Net (Loss) Income under Significant Expense Principle The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three months ended March 31, 2026 and 2025 (in thousands):

 

 

For the Three Months
Ended March 31,

 

 

2026

 

 

2025

 

 

 

 

 

 

 

Collaboration Revenue

 

$

20,000

 

 

$

 

Research and Development Expenses:

 

 

 

 

 

 

RAP-219 program external expenses

 

 

15,821

 

 

 

7,963

 

Preclinical programs external expenses

 

 

4,289

 

 

 

3,246

 

R&D personnel-related costs (including stock-based
   compensation)

 

 

10,640

 

 

 

6,786

 

 Other costs

 

 

1,966

 

 

 

1,577

 

Selling, General and Administrative Expenses:

 

 

 

 

 

 

G&A personnel-related costs (including stock-based
   compensation)

 

 

6,983

 

 

 

4,959

 

Professional and consulting costs

 

 

3,672

 

 

 

1,664

 

Facility related and other

 

 

844

 

 

 

913

 

Loss from operations

 

$

(24,215

)

 

$

(27,108

)

Interest income

 

 

4,358

 

 

 

3,045

 

Net loss

 

$

(19,857

)

 

$

(24,063

)